NCT06216938
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatmentYana NajjarInvestigator-initiated
~25 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Vusolimogene oderparepvec (RP1)
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of Sentinel Lymph Node (SLN) Positivity
Measured over Up to 2 years (cohort)
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Yana Najjar, MD · PRINCIPAL_INVESTIGATOR · UPMC Hillman Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Rate of Sentinel Lymph Node (SLN) PositivityUp to 2 years (cohort)
Proportion of patients with sentinel lymph node lymph node positivity (disease present in lymph node per pathologic assessment).